GLP-1 Hair-Loss Studies: Rates, Comparators and Diagnosis

When you read about hair loss during GLP-1 treatment, check whether the number describes diagnoses, reported symptoms, or a change in hair density. Those measurements answer different questions. Keep the outcome and comparison group beside the headline before discussing a treatment decision.

What the Penn Medicine study measured

Tang and colleagues used Penn Medicine records for adults with type 2 diabetes starting treatment in January 2019–September 2024. Their target trial emulation used observational data, not random assignment. New hair-loss diagnoses were identified by codes. [1]

After adjustment, the comparison with SGLT-2 inhibitors, another class of diabetes medicines, gave these rates: [1]

The adjusted hazard ratio was 1.37 (95% confidence interval 1.08–1.73). This is a relative comparison, not 37% of patients developing alopecia. Person-years combine people's observation time; these rates are not a measured one-year probability for every patient. [1]

The authors acknowledge unmeasured confounding. The finding does not establish the same risk in people without diabetes. NIH supported the work; two authors reported unrelated consulting or research relationships. Our review used the abstract and accessible publisher sections, not a complete supplementary-data review. [1]

A second study examined diagnostic categories

Katragadda and colleagues analyzed TriNetX records from 2018–2025, matching GLP-1 users with nonusers on recorded characteristics. They separated diabetes and obesity indications. Semaglutide and tirzepatide were associated with higher odds of nonscarring hair loss. Follow-up windows differed: one, three and five years for semaglutide; one, one-and-a-half and two years for tirzepatide. [2]

The abstract reports no association with alopecia areata. It does not provide the group sizes or numerical effect estimates, so this article does not assign a percentage from that report. This was an abstract-level review; the publisher reports no author conflicts. [2]

These studies use different comparison groups and analyses. Their findings should not be arranged into a drug ranking by placing an odds ratio from one beside a hazard ratio from another. Neither comparison tells you what would happen to your own hair if you switched prescriptions.

A recorded diagnosis is not a count of shed hairs

A person noticing extra hair in the shower and a clinician entering an alopecia code are different observations. When discussing these papers, keep the outcome attached to the number: clinically recorded alopecia. Do not translate it into the amount of thinning, the number of hairs lost each day, or the likelihood of regrowth.

If you have noticed a change, describe it without forcing it into a study category. “My usual part looks wider” and “I am finding more loose hairs when washing” are useful starting descriptions. Tell the clinician if you have noticed both. Ask what examination is needed to identify the cause before selecting a hair-growth product.

The American Academy of Dermatology explains that assessment includes onset, speed of change, scalp and nail examination, and hair health. Blood tests or a scalp biopsy may be appropriate when the clinician suspects an underlying disorder, deficiency, hormonal problem or infection. More than one cause can occur together. [3]

Keep the hair question in the treatment discussion

Ask your prescriber: “I have noticed this change since this date. How should we investigate it while reviewing the benefits and side effects of my treatment?” Bring the medicine name, dose history and a list of supplements. Do not stop or switch a prescription on the strength of a population comparison.

If someone recommends iron, zinc or biotin for the shedding, ask what finding supports that choice. AAD advises using these supplements for a demonstrated deficiency; taking extra when levels are normal can cause harm. [3]

Write down the assessment plan and who will review it. A hair concern deserves discussion even when it does not change the prescription decision. The next useful answer is the cause being considered and the plan for checking it, rather than a promise based on a headline.

Printed book

How to Keep Your Face on GLP-1

$12.95 + free shipping

Order Now

✓ 30 day money back guarantee

This article provides general education, not a diagnosis or an individual treatment plan. Medication information refers to US sources. Discuss medication, nutrition and cosmetic treatment decisions with qualified clinicians.